Tango Therapeutics (TNGX) said Wednesday that the first patient has been dosed in its phase 1/2 trial to treat patients with methylthioadenosine phosphorylase-deleted solid tumors, with a focus on glioblastoma.
TNG456 is a brain-penetrant, MTA-cooperative PRMT5 inhibitor, the company said.
"People with GBM currently have few treatment options and a five-year survival rate below 10%," Adam Crystal, president, research and development of Tango Therapeutics, said in a statement. "A substantial number of patients have the potential to benefit from TNG456."
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.